Loading patent…
AssigneeFred Hutchinson Cancer Center
InventorsKristin LASTWIKA, Paul LAMPE, Ashley MCGARRY HOUGHTON
Estimating the term…
Disclosed herein are high performance biomarkers and panels for small cell lung cancer (SCLC) early detection useful for identifying, diagnosing, and treating SCLC patients at an early stage. The method of diagnosing and treating SCLC in a subject can include detecting presence of autoantibodies that specifically bind one or more epitopes of antigens in a biological sample obtained from the subject, wherein the one or more epitopes of the antigens comprises a post-translational modification; diagnosing the subject with SCLC when the presence of the autoantibodies is detected in the biological sample; and treating the SCLC in the subject by administering a chemotherapy regimen, an immunotherapy regimen, an antibody, performing a surgery, and/or radiotherapy. In one example, the post-translational modifications targeted by the autoantibodies include citrullination, isoaspartylation and/or cancer-specific glycosylation.
A method of treating small cell lung cancer (SCLC) in a subject, the method comprising:
A method of diagnosing and treating small cell lung cancer (SCLC) in a subject, the method comprising:
A biomarker detection panel for small cell lung cancer (SCLC), comprising one or more peptides comprising an epitope of from 7 to 50 amino acids in length from one or more antigens selected from the group consisting of CDH5, CD133, SPINK1, CDH23, NLRP7, TFRC, SPINT2, NADSYN1, HIF1A, GRAP2, MAPRE1, INHA, PTEN, CTSB, B3GNT6, PLD3, TIMP2, NUDT2, ANAPC2, GPLD1, PTPRU and CA9, wherein the epitope comprises a post-translational modification (PTM) bound by an autoantibody.
An isolated antibody or antigen binding fragment thereof that binds to an epitope of TFRC-4 comprising a PTM, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
The antibody or antigen-binding fragment of any one of claims 76-79, wherein the epitope comprises the amino acid sequence of SEQ ID NO:
An antibody or antigen binding fragment thereof that binds to an epitope of CA9-3 comprising a PTM, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
An antibody or antigen binding fragment thereof that binds to an epitope of TFRC-5 comprising a PTM, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
An antibody or antigen binding fragment thereof that binds to an epitope of TFRC-1 or TFRC-2 comprising a PTM, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
An antibody or antigen binding fragment thereof that binds to an epitope of SPINK1-1 comprising a PTM, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.